Ghisallo Capital Management’s Xilio Therapeutics XLO Stock Holding History

Ghisallo Capital Management’s Portfolio XLO Stock Details XLO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$116K	Sell	13,800 -65,716	-83%	-$538K	﹤0.01%	271
2025 Q4	$713K	Buy	+79,516	New	+$835K	0.03%	189
2025 Q3	–	Sell	-95,214	Closed	-$906K	–	258
2025 Q2	$906K	Buy	+95,214	New	+$1.01M	0.02%	170
2022 Q1	–	Sell	-2,143	Closed	-$480K	–	415
2021 Q4	$480K	Buy	+2,143	New	+$511K	0.02%	414

Other funds holding XLO

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Sio Capital Management New York $694M AUM 79.73% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Caligan Partners New York $1.41B AUM 518.95% 1-Year Est. Return

Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return

Stonepine Capital Management Bend, Oregon $114M AUM 77.6% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Renaissance Technologies

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return